| Literature DB >> 27433379 |
Jieun Kim1, Yangsoon Lee2, Yongjung Park3, Myungsook Kim1, Jun Yong Choi4, Dongeun Yong1, Seok Hoon Jeong1, Kyungwon Lee1.
Abstract
BACKGROUND: Investigation on incidence and mortality of anaerobic bacteremia (AB) is clinically relevant in spite of its infrequent occurrence and not often explored, which report varies according to period and institutions. Therefore, it is necessary to analyze the incidence and risk factors related to mortality and assess clinical outcomes of AB in current aspect.Entities:
Keywords: Anaerobic bacteremia; Inappropriate therapy; Mortality; Survival rate
Year: 2016 PMID: 27433379 PMCID: PMC4945732 DOI: 10.3947/ic.2016.48.2.91
Source DB: PubMed Journal: Infect Chemother ISSN: 1598-8112
Host or microbial characteristics associated with 28-day mortality in 70 patients of anaerobic bacteremia
| Characteristics/factors | No. (%) of patients | ||||
|---|---|---|---|---|---|
| All (No=70) | Alive (No =55) | Dead (No =15) | Univariatea | Multivariateb | |
| Age (median, interquartile range, years) | 61 (50-69) | 61 (48-69) | 60 (50-77) | 0.897 | |
| Age > 60 years | 35 (50.0) | 28 (50.9) | 7 (46.7) | 0.771 | |
| Male/Female (male, %) | 38/32 (54.3) | 33/22 (60.0) | 5/10 (33.3) | 0.066 | 0.050 |
| Underlying diseases, n (%) | |||||
| Hematologic malignancy | 6 (8.6) | 4 (7.3) | 2 (13.3) | 1.000 | |
| Non-hematologic malignancy | 50 (71.4) | 39 (70.9) | 11 (73.3) | 0.749 | |
| Cardiovascular disease | 11 (15.7) | 6 (10.9) | 5 (33.3) | 0.049 | 0.045 |
| Previous surgery | 27 (38.6) | 21 (38.2) | 6 (40.0) | 0.898 | |
| Diabetes mellitus | 9 (12.9) | 7 (12.7) | 2 (13.3) | 1.000 | |
| Liver disease | 14 (20.0) | 10 (18.2) | 4 (26.7) | 0.480 | |
| Source of infection, n (%) | |||||
| Intra-abdominal | 42 (60.0) | 34 (61.8) | 8 (53.3) | 1.000 | |
| Skin barrier penetration | 5 (7.1) | 5 (9.1) | 0 (0.0) | 0.577 | |
| Respiratory | 2 (2.9) | 1 (1.8) | 1 (6.7) | 1.000 | |
| Origin of infection, n (%) | |||||
| Hospital-acquired infection | 44 (62.9) | 32 (58.2) | 12 (80.0) | 0.1210 | 1.000 |
| Community-acquired infection | 2 (2.9) | 2 (3.6) | 0 (0.0) | 1.000 | |
| Healthcare-associated community onset infection | 24 (34.3) | 21 (38.2) | 3 (20.0) | 0.189 | 1.000 |
| Polymicrobial infection | 9 (12.9) | 3 (5.5) | 6 (40.0) | 0.392 | |
| 50 (71.4) | 37 (67.3) | 13 (86.7) | 0.202 | ||
| Inappropriate therapy | 16 (22.9) | 10 (18.2) | 6 (40.0) | 0.139 | 0.168 |
aThe Pearson χ2 test was used for categorical variables and the Mann-Whitney U test was used for continuous variables.
bThe multivariate logistic regression analysis was used to determine which variables were acting independently.
Anaerobic organisms isolated from blood culture
| Organisms | No.(%) of patients |
|---|---|
| 32 (45.7) | |
| 10 (14.3) | |
| 4 (5.7) | |
| 2 (2.9) | |
| 2 (2.9) | |
| 1 (1.4) | |
| 1 (1.4) | |
| 9 (12.9) | |
| 1 (1.4) | |
| 1 (1.4) | |
| 3 (4.3) | |
| 4 (5.7) | |
| Total | 70 (100.0) |
Antimicrobial activities against 44 Bacteroides fragilis group isolates in 2012
| Antimicrobial agents | ||||||||
|---|---|---|---|---|---|---|---|---|
| MIC (µg/mL) | % Susceptibilitya | MIC (µg/mL) | % Susceptibilitya | |||||
| Range | 90% | S | R | Range | 90% | S | R | |
| Piperacillin | 2->256 | 128 | 75 | 13 | 128->256 | >256 | 0 | 100 |
| Piperacillin-tazobactam | 0.25-128 | 2 | 97 | 3 | 0.03-256 | 128 | 75 | 17 |
| Cefoxitin | 8-128 | 16 | 91 | 9 | 4-64 | 32 | 25 | 8 |
| Cefotetan | 4-256 | 32 | 81 | 9 | 8-256 | 256 | 17 | 67 |
| Imipenem | 0.06-32 | 1 | 97 | 3 | 0.06-8 | 8 | 83 | 0 |
| Meropenem | 0.12-256 | 1 | 91 | 6 | 0.125-4 | 2 | 100 | 0 |
| Clindamycin | 0.03-256 | 256 | 50 | 50 | 2-256 | 256 | 17 | 67 |
| Moxifloxacin | 0.25-32 | 8 | 78 | 16 | 0.5-64 | 32 | 75 | 25 |
| Chloramphenicol | 4-8 | 8 | 100 | 0 | 4-8 | 8 | 100 | 0 |
| Metronidazole | 0.5-4 | 4 | 100 | 0 | 1-2 | 2 | 100 | 0 |
aS, susceptible; R, resistant.
bBacteroides thetaiotaomicron (n=6), B. caccae (n=2), B. ovatus (n=2), B. vulgatus (n=2).
Figure 1Clinical outcome and survival rate of 70 patients with anaerobic bacteremia according to appropriateness of treatment(A, B).